ImmunityBio falls 18% as Anktiva sales slip, overshadowing a trial win
Why is ImmunityBio stock down today?
ImmunityBio's sales of Anktiva, its bladder-cancer drug, fell from the second quarter for the first time since its launch, and total revenue of $48.8 million missed the $59.2 million estimate from Fiscal.ai, cited by Stocktwits. The same morning it said a registrational trial in newly diagnosed patients met its main goal, but it gave no response rates. The shares closed down about 18% on a day biotech stocks rose, after rising about 336% from the end of 2025 through Friday (Yahoo Finance closes; our calculation).
What it means
- What changed
- Anktiva sales fell quarter on quarter for the first time since launch, after eight straight rises. Total revenue missed estimates by about $10 million.
- What hasn't changed
- Sales were still up 53% from a year earlier, the label widened in October, and ImmunityBio still plans a new FDA filing by year-end.
- Next · By the end of 2026 (company plan)
- ImmunityBio's FDA filing to use Anktiva plus BCG in patients receiving BCG for the first time.
- Move
- ▼ 17.7%
- Price
- $8.64 → $7.11
- Value lost
- ~$1.6B
- Q3 total revenue
- $48.8M vs ~$59.2M est.
- Anktiva sales vs Q2
- $48.7M vs $50.7M
- Cash and securities
- $334.3M (Sep 30)
Prices: Official close via Yahoo Finance and CNBC, Nov 9, 2026 · Company data: 10-Q, Sep 30, 2026 · What these numbers mean
Closing prices on Nov 9, 2026, from Yahoo Finance and CNBC. The previous close is the official Nov 6 close. Market value uses 1,063,826,073 common shares on Nov 3 (10-Q cover). Debt is at balance-sheet carrying value, including the related-party convertible note at fair value ($834.9M; principal $480.0M).
Snapshot at the Nov 9, 2026 close
- Market value
- $7.6B
- Enterprise value
- $8.5B
- Price/sales
- 41.4×
- EV/sales
- 46.5×
- P/E
- n/m
- Price/FCF
- n/m
- Revenue growth
- +121%
- FCF margin
- −163%
- Net debt
- $927M
Our calculation from the company's filings (latest: 10-Q for the quarter to Sep 30, 2026, filed Nov 9, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Sep 30, 2026. Price $7.11 (Official close via Yahoo Finance and CNBC); 1063.8 million shares (common shares on the cover page of the 10-Q filed Nov 9, 2026). n/m = not meaningful (e.g. negative earnings).
Price data
| Date | Close |
|---|---|
| Oct 1, 2026 | $9.28 |
| Oct 2, 2026 | $10.28 |
| Oct 5, 2026 | $10.38 |
| Oct 6, 2026 | $9.69 |
| Oct 7, 2026 | $9.75 |
| Oct 8, 2026 | $9.91 |
| Oct 9, 2026 | $10.51 |
| Oct 12, 2026 | $10.12 |
| Oct 13, 2026 | $9.80 |
| Oct 14, 2026 | $9.91 |
| Oct 15, 2026 | $10.00 |
| Oct 16, 2026 | $9.18 |
| Oct 19, 2026 | $8.42 |
| Oct 20, 2026 | $8.77 |
| Oct 21, 2026 | $8.64 |
| Oct 22, 2026 | $8.31 |
| Oct 23, 2026 | $8.22 |
| Oct 26, 2026 | $7.81 |
| Oct 27, 2026 | $8.63 |
| Oct 28, 2026 | $8.81 |
| Oct 29, 2026 | $8.74 |
| Oct 30, 2026 | $8.29 |
| Nov 2, 2026 | $7.95 |
| Nov 3, 2026 | $8.29 |
| Nov 4, 2026 | $8.93 |
| Nov 5, 2026 | $8.01 |
| Nov 6, 2026 | $8.64 |
| Nov 9, 2026 | $7.11 |
What happened
ImmunityBio sells one drug, Anktiva, which doctors put into the bladder together with BCG, the standard treatment, for early bladder cancer that BCG alone no longer controls. Two releases came out before Monday’s open.
- Sales went backwards. Anktiva brought in $48.7 million in the third quarter, up 53% from a year earlier but down from $50.7 million in the second quarter. In August ImmunityBio had called the second quarter its eighth straight quarter of sales growth since the 2024 launch, so this was the first quarter-on-quarter fall (our calculation from its releases). Total revenue of $48.8 million was about $10 million below the $59.2 million analysts expected, according to Fiscal.ai data cited by Stocktwits and MarketBeat. The company gave no reason for the drop.
- A trial succeeded, without numbers. In a separate release ImmunityBio said Anktiva plus BCG beat BCG alone on the main goal of QUILT-2.005, a 370-patient trial in people receiving BCG for the first time, in the carcinoma in situ form of the disease. It gave no response rates and said details will come at an upcoming medical congress. It plans to ask the FDA by the end of 2026 to add these patients to the label.
- The FDA label news was older. The results release also listed the FDA’s Oct 14 approval widening Anktiva’s label to patients whose tumours are papillary only, which ImmunityBio announced that day, nearly three months before the agency’s January 2027 deadline, plus approval in Israel, its 35th country.
The quarterly loss widened to $184.6 million from $67.3 million. Most of the increase came from a $77.9 million paper charge, against a $14.0 million gain a year earlier, from the rising value of a convertible loan from Nant Capital, a company tied to founder and executive chairman Patrick Soon-Shiong, and of warrants and other derivatives, which the company said reflected its higher share price during the quarter. Removing only the fair-value changes leaves a loss of $106.6 million, against $81.3 million a year earlier (our calculation: the $77.917 million charge taken off the $184.550 million loss, and last year’s $14.025 million gain added back to its $67.253 million loss, rounded after). The company’s own adjusted loss, which also excludes stock-based pay, was $97.9 million.
The shares closed down 17.7% at $7.11, after opening at $7.22 and falling as low as $6.36 (Yahoo Finance and CNBC). The SPDR S&P Biotech ETF (XBI) closed up 3.1% (Yahoo Finance and CNBC).
ImmunityBio's quarterly Anktiva sales, 2025 to 2026
Sales fell in the third quarter of 2026 for the first time since launch, to $48.7 million from $50.7 million, against total-revenue estimates of $59.2 million.
Show the data table
| Quarter | Anktiva net product revenue ($M) |
|---|---|
| Q1 2025 | 16.5 |
| Q2 2025 | 26.4 |
| Q3 2025 | 31.8 |
| Q4 2025 | 38.3 |
| Q1 2026 | 44.2 |
| Q2 2026 | 50.7 |
| Q3 2026 | 48.7 |
Why the market reacted this way
Investors had been paying for fast growth, and the quarter showed sales stalling just as the company widened its market.
- The miss was large for a one-drug company. Revenue came in about 18% below the estimate (our calculation), and Stocktwits said it was ImmunityBio’s first revenue miss in six quarters. With no explanation from the company, investors couldn’t tell whether the dip was a one-off or a slowdown.
- The good news was harder to price. The trial release gave no figures, so the size of the benefit in newly diagnosed patients isn’t known yet, and that market depends on a filing the FDA hasn’t received. The label expansion was already public. Before this report, Jefferies, an investment bank, had raised its target to $14 from $12 with a Buy rating, MarketBeat reported.
- Investing.com put the fall down to “a significant revenue shortfall, a deepening net loss, an active going-concern disclosure and insider selling.” The going-concern wording, that “substantial doubt exists” without more funding or support, also appeared in the June 10-Q; the company says its cash and the founder’s support alleviate it. The two director sales were in early October, under pre-arranged trading plans.
- The stock had a long way to fall. It had more than quadrupled this year, from $1.98 at the end of 2025 to $8.64 on Friday, and at that price ImmunityBio was valued at about $9.2 billion, roughly 50 times the $182.6 million of revenue it reported over the past 12 months (our calculation).
Does this change ImmunityBio’s future?
What did NOT change
Anktiva is still growing fast from a year ago, up 92% in the first nine months to $143.6 million, and its US label now covers all BCG-unresponsive patients with this early form of bladder cancer. ImmunityBio ended September with $334.3 million in cash and marketable securities and used $75.3 million in its operations during the quarter. It raised $28.5 million by selling shares in the market during the quarter.
What DID change
In August ImmunityBio reported a 15% sequential rise; now sales are 4% lower than in the second quarter (our calculation), and the company hasn’t said why. The trial in newly diagnosed patients moved from a plan to a positive top-line result, but without the numbers that would show how large the new market could be.
Our read
Our interpretation is that investors weighed a stall in the only drug ImmunityBio sells more heavily than a trial result whose size they can’t yet judge. The October label expansion gives Anktiva more patients to reach, while use in newly diagnosed patients still needs FDA approval after the planned filing. Fourth-quarter sales will cover only part of a quarter under the wider label; the first full one will be the first quarter of 2027.
The other view
Going into the report, analysts were mostly positive: six rated the stock Buy and one Sell, with an average price target of $16.00, MarketBeat's data showed.
Source: MarketBeat: ImmunityBio announces earnings results, Nov 9
What to watch next
- By the end of 2026 (company plan)
- ImmunityBio's supplemental FDA application for Anktiva plus BCG in newly diagnosed (BCG-naive) bladder cancer.
- Not yet scheduled
- The full QUILT-2.005 results, which ImmunityBio says it will present at an upcoming medical congress, including the response rates it hasn't released.
- Early 2027 (expected)
- Fourth-quarter sales, covering the first months after the October label expansion.
Quick questions
What is the difference between BCG-unresponsive and BCG-naive bladder cancer?
BCG, a weakened tuberculosis bacterium put into the bladder, is commonly used after tumour removal for bladder cancer at intermediate or high risk that hasn't grown into the muscle. BCG-unresponsive patients have already had BCG and it stopped working; that's where Anktiva is approved. BCG-naive patients haven't had BCG yet, a larger group that today's trial covered.
Why was ImmunityBio's loss so large?
The biggest single item in the $184.6 million quarterly loss was a $77.9 million paper charge from the rising value of a convertible loan from a company tied to founder Patrick Soon-Shiong and of warrants and other derivatives, which grow more valuable to their holders as the share price rises. Without the fair-value changes, the loss would have been $106.6 million (our calculation); the company's own adjusted loss, which also excludes stock-based pay, was $97.9 million.
Updates
- : Updated to the Nov 9 close: down 17.7% at $7.11.
About ImmunityBio: Website (external site)Investor relations (external site)SEC filings (external site)
+ 11 more
Accessed Nov 9, 2026: ImmunityBio: Q3 2026 Form 10-Q, Nov 9 · FDA: expanded indication for Anktiva (nogapendekin alfa inbakicept-pmln), Oct 14 · ImmunityBio: 2025 Form 10-K · ImmunityBio: FDA expands Anktiva approval (SEC 8-K, Exhibit 99.1), Oct 14 · ImmunityBio: second-quarter 2026 results (SEC 8-K, Exhibit 99.1), Aug 4 · ImmunityBio: Q2 2026 Form 10-Q, Aug 4 · MarketBeat: ImmunityBio announces earnings results, Nov 9 · Investing.com: Why is Immunitybio stock sliding today?, Nov 9 · Yahoo Finance: IBRX, index and ETF prices, Nov 9 · Yahoo Finance: XBI historical prices, Nov 9 · CNBC: IBRX and XBI quotes, Nov 9 close
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.